^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    conteltinib (SY-707)

    i
    Company:
    Centaurus Biopharma, Shouyao Holdings
    Drug class:
    ALK inhibitor, Multi-tyrosine kinase inhibitor, IGF-1R inhibitor, FAK inhibitor, Pyk2 inhibitor
    Related drugs:
    Apply
    Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02695550)
    Phase 1
    Centaurus Biopharma Co., Ltd.
    Unknown status
    Last update posted :
    03/09/2017
    Initiation :
    03/01/2016
    Primary completion :
    03/01/2018
    Completion :
    03/01/2018
    ALK
    |
    ALK positive • ALK rearrangement
    |
    Xalkori (crizotinib) • conteltinib (SY-707)